Highly selective inhibitors of the urokinase plasminogen activator

US7049344B2 · kind B2 · utility

Assignees

• Wilex Biotechnology GmbH · DE
• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Viktor Magdolen · Tauberbischofsheim, DE
• Stefan Sperl · Birkenfeld, DE
• Joerg Stuerzebecher · Erfurt, DE
• Olaf Wilhelm · Birkenfeld, DE
• Nuria Arroyo De Prada · Barcelona, ES
• Luis Moroder · Martinsried, DE
• Robert Huber · Midland, US
• Uwe Jacob · Birkenfeld, DE
• Wolfram Bode · Gauting, DE

Key dates

• Filing date: Nov 22, 2004
• Grant date: May 23, 2006
• Expiry date: Nov 22, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2603/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method is described for inhibiting urokinase plasminogen activator in a human or animal patient. The method involves administering to the patient a urokinase plasminogen activator inhibiting effective amount of a compound of the formula (I):